Exsurco Medical

What Exsurco Medical does

Exsurco Medical, Inc. is a privately held, Ohio-based medical device manufacturer and wholly-owned subsidiary of Bettcher Industries, Inc. Founded in 2011, the company designs and produces precision pneumatic and electric surgical devices for skin grafting, wound debridement, and tissue recovery, serving two distinct customer segments: tissue banks that recover and process cadaveric allograft skin, and burn/trauma surgical teams in hospitals and burn centers.

The core product family is the Amalgatome line — Amalgatome MD (split-thickness tissue recovery with rotary excision ring and Edge-Retention Technology), Amalgatome SK (full-thickness tissue processing with adipose removal), and Amalgatome SD (pneumatically powered surgical device combining skin grafting and debridement) — supplemented by the 2023-launched Mesh|EX manual graft meshing system. Underlying technology centers on a rotating circular excision blade architecture that enables maneuverability over body contours and hard-to-reach areas, with proprietary edge-retention blade processing preserving sharpness across procedures. Devices are manufactured in an ISO 13485:2016-certified Class 7 cleanroom in Wakeman, OH; the Amalgatome SD is FDA-registered as a Class I device and CE-marked for European markets.

The company operates a razor-and-blade revenue model: capital equipment sales of reusable devices (one-year warranty, undisclosed pricing) anchor the installed base, while recurring revenue comes from sterile disposable blades priced $855-$1,604 per box, plus sterilization trays, transportation cases, and accessories. Distribution is primarily via a direct US enterprise sales force covering major metros, with European distribution in Germany, UK, Netherlands, and France targeting the tissue bank segment. The GTM motion relies on free clinical evaluations, in-service training, peer-reviewed clinical publications, and presence at major burn/trauma conferences. Customers include at least 33 US tissue banks across 21 states and named burn centers such as Grossman Burn Center, Texas Tech, and Orange County Burn Center.

Name

Exsurco Medical

Legal name

Exsurco Medical, Inc.

Website

https://exsurco.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Exsurco Medical is a medical device manufacturer that designs precision Amalgatome surgical and tissue recovery devices (skin grafting, wound debridement, and cadaveric allograft recovery) for tissue banks, burn centers, and trauma hospitals in the US and Europe.

Ownership category

akta.pro rank

Headquarters

HQ city

Wakeman

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Medical Device Sales (Capital Equipment): Sale of reusable surgical and tissue processing devices including Amalgatome SD, MD, and SK systems. These are capital equipment purchases with one-year warranty coverage.
2. Disposable Blades and Consumables: Recurring revenue from sterile, disposable blades (Amalgatome SD Excision Ring Blades, Amalgatome MD Blades, Amalgatome SK Blades) and single-use components. Sold in boxes (5 or 10 per box) at various price points ($855.70-$1,604.00 per box).
3. Accessories and Replacement Parts: Sale of accessories including sterilization trays, transportation cases, autoclavable screwdrivers, pin drivers, and other replacement parts for device maintenance.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Exsurco Medical manufactures and sells precision medical devices for skin grafting, wound debridement, and cadaveric tissue recovery. Its core product family, the Amalgatome line (Amalgatome SD, MD, and SK), uses proprietary rotary excision ring technology with Edge-Retention Technology, alongside the Mesh|EX skin graft meshing device, supported by sterile disposable blades and accessories.

Product overview

Exsurco Medical offers a portfolio of precision medical devices for skin grafting and tissue recovery, organized into two main market segments: Tissue Banks (for cadaveric use) and Healthcare Professionals (for surgical/patient use). The core products are the Amalgatome family of devices - Amalgatome SD (surgical skin grafting and wound debridement), Amalgatome MD (split-thickness tissue recovery), and Amalgatome SK (full-thickness tissue processing) - along with the Mesh|EX skin graft meshing device. These products share common rotary/excision ring blade technology and are supported by disposable blade accessories and sterilization/transport accessories.

Differentiator

Problem solved

Functional benefit

Brands

• Amalgatome: Product line of skin recovery and grafting devices including Amalgatome MD (tissue banks), Amalgatome SK (full-thickness tissue processing), and Amalgatome SD (surgical/wound debridement).
• Mesh|EX

Products and services

• Amalgatome SD Pneumatically powered, reusable surgical skin grafting and wound debridement device for use in operating rooms on burn and trauma patients. Produces skin grafts from 0.005" to 0.045" thickness in 0.001" increments and performs necrotic tissue and eschar removal.
• Amalgatome MD Split-thickness skin recovery device with proprietary rotary design and Edge-Retention Technology for tissue banks. Used for cadaveric skin recovery with maneuverability over body contours and hard-to-reach areas. Adjusts in 0.001" increments to produce grafts up to 0.040".
• Amalgatome SK

Quantifiable outcome

• 48% increase in transplantable skin yield for tissue banks using the device during trial evaluation
• +7 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Phoenix Society for Burn SurvivorscoreOthersExsurco is a proud partner and corporate sponsor of Phoenix Society for Burn Survivors, supporting the community of burn survivors, their loved ones, health professionals, and firefighters. The company sponsors their annual conference and aims to help raise awareness of the importance of burn care and prevention.
• Donate Life AmericacoreOthersCorporate sponsor of Donate Life America, supporting efforts to spread awareness about the importance of tissue, organ, and eye donation. Exsurco Medical supports the gift of skin donation to help promote healing for those in need.
• Bettcher Industries, Inc.coreStrategic or Co-development PartnerExsurco Medical is a wholly-owned subsidiary of Bettcher Industries, Inc. Founded in 2008 when Bettcher leadership began exploring applications for their precision cutting technology in the medical marketplace. Bettcher is a market leader in patented precision cutting and trimming tools for food processing and industrial manufacturing.
• BioEnterpriseminorOthersHealthcare venture formation organization that provided strategic counsel to Bettcher Industries, providing access to non-dilutive funding sources and expertise in early-stage business formation and marketing in the healthcare space during Exsurco's founding.
• Spiegel Burn FoundationminorOthersFoundation focused on assisting survivors of burns and burn-related injuries. The foundation has assisted Exsurco in working with individual burn centers to provide the Amalgatome SD surgical device for skin grafting and wound debridement.

Scale indicators8 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Organogenesis: Regenerative medicine and tissue-based product company serving wound care and surgical markets with skin substitutes. Competes for the same downstream clinical indications (burns, chronic wounds) that Exsurco's devices support.
• MTF Biologics: One of the largest US tissue banks and allograft providers. As an Exsurco tissue-bank customer-side partner, MTF represents both a user of Amalgatome MD for cadaveric skin recovery and a peer in the allograft value chain Exsurco's devices enable.
• AlloSource: Not-for-profit tissue bank producing skin allografts — a direct customer-side peer using Amalgatome MD for split-thickness cadaveric skin recovery. Closely mirrors the tissue-bank half of Exsurco's customer base.

Broad incumbents

• Integra LifeSciences: Major diversified surgical device and wound-care company with strong position in burn and reconstructive surgery markets where Exsurco's Amalgatome SD competes. Sells a broad portfolio including traditional dermatomes and regenerative skin substitutes that compete for the same OR budgets.
• Smith+Nephew: Global wound management leader with burn care and advanced wound therapy products sold into the same burn-center and hospital channels that Exsurco targets. Its size and bundled solutions pose direct competitive risk to the Amalgatome SD.
• Coloplast: Established wound and skin care device company with surgical wound management products sold into hospitals and burn centers. Operates in adjacent wound-care niches that compete for the same clinical budget.
• Zimmer Biomet: Large orthopedic and surgical device company with a dermatome product line sold into reconstructive and burn surgery ORs. Competes directly with Amalgatome SD in hospitals that already own Zimmer dermatomes.
• B. Braun / Aesculap: Incumbent manufacturer of traditional dermatomes and surgical instruments used in the same skin graft harvesting procedures. Its established dermatome installed base represents the primary installed-equipment competitor to Amalgatome.
• Mölnlycke Health Care: Specialist in wound care and burn treatment (Mepilex, Avance) serving burn centers and ORs globally. Operates in the same clinical segment for burn wound debridement and skin graft procedures that Exsurco's devices support.

Emerging players

• Vericel: Specialty biologics company focused on severe burn and wound care (Epicel autologous skin grafts). Competes with Amalgatome-enabled allografts for the same burn-care treatment pathways and surgeon mindshare.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubevimeo.com/user184847659

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exsurco Medical